FDA Approves New Combination Therapy for Stage III Colon Cancer

The U.S. FDA has approved atezolizumab (Tecentriq) combined with fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III mismatch repair-deficient (dMMR) colon cancer in adults and pediatric patients aged two and older. This decision, based on the Phase 3 ATOMIC/ML39057 trial, showed improved disease-free survival. The approval offers a new treatment option for a specific type of colon cancer, potentially improving patient outcomes.